Purchase orders / AR absolutely affect fundamentals. You don't know what fundamental valuation is. What about that list conflicts with the fact that the shares are trading multiples above book value, and not below ("undervalued" was your assessment), pray tell?
Posted On: 09/17/2021 6:15:05 PM
Post#
104390
of 104418
Avatar
Posted By: JLang
Sure, it's all a big surprise from that thing that CytoDyn's been talking about for months..
Nothing to do with NASH results forthcoming
Nothing to do with multiple Oncology revelations
Nothing to do with **3rd PO from Philippines**
Nothing to do with research partnerships with academic institutions
Nothing to do with investor conferences
Nothing to do with HGEN's EUA denial..
These are all new catalysts from the past week. None of those would cause anyone to re-evaluate CYDY's prospects, but that trial that was approved weeks ago, that was what finally did it.
Posted On: 09/17/2021 6:15:05 PM
Post#
104390
of 104418
Avatar
Posted By: JLang
Sure, it's all a big surprise from that thing that CytoDyn's been talking about for months..
Nothing to do with NASH results forthcoming
Nothing to do with multiple Oncology revelations
Nothing to do with **3rd PO from Philippines**
Nothing to do with research partnerships with academic institutions
Nothing to do with investor conferences
Nothing to do with HGEN's EUA denial..
These are all new catalysts from the past week. None of those would cause anyone to re-evaluate CYDY's prospects, but that trial that was approved weeks ago, that was what finally did it.
